Eli Lilly Maintains Lead in Diabetes Drug Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Increased Market Competition: While Novo Nordisk showcased positive data for its weight-loss drug CagriSema at the ADA conference, RBC analyst Trung Huynh emphasized that Eli Lilly's lead in the diabetes drug market remains solid, indicating its competitive advantage.
- Significant Clinical Trial Results: Eli Lilly's presentation of retatrutide (triple G) at the ADA conference revealed meaningful improvements in patients suffering from knee osteoarthritis and sleep apnea, further solidifying its market position in weight-loss and diabetes management.
- Strong Financial Performance: Eli Lilly reported a remarkable 56% revenue growth last quarter, driven by the successful launch of new weight-loss and diabetes drugs, showcasing its sustained high growth potential, particularly with the successful market entry of Zepbound and Mounjaro.
- Notable Valuation Gap: Currently, Novo Nordisk's forward P/E ratio stands at 13.6 times, while Eli Lilly's is at 30 times, indicating that the valuation gap between the two may persist unless Novo Nordisk returns to positive growth or Eli Lilly's growth rate significantly slows down.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1117.260
Low
950.00
Averages
1192
High
1500
Current: 1117.260
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lilly Launches MedicareGLP-1Bridge Program for Obesity Treatments
- New Medicare Pathway: Lilly announced the MedicareGLP-1Bridge program effective July 1, 2026, allowing eligible Medicare Part D patients to access Foundayo and Zepbound for $50 per month, marking a significant increase in treatment options for obesity.
- Expanded Coverage: This program will provide broad GLP-1 drug coverage for Medicare Part D patients for the first time, potentially benefiting around 20 million eligible patients and promoting obesity treatment accessibility, particularly among adults aged 65 and older.
- Significant Clinical Outcomes: Clinical trials demonstrated that Foundayo and Zepbound resulted in meaningful weight loss in patients aged 65 and older, with Foundayo achieving an average weight loss of 13% in non-diabetic patients at the highest dose, while Zepbound showed over 56.7% of patients losing at least 20% of their body weight over 72 weeks, highlighting its effectiveness in older populations.
- Long-term Strategic Implications: This initiative not only enhances the accessibility of Lilly's obesity medications but also solidifies its leadership in chronic disease treatment, reflecting the company's commitment to recognizing obesity as a chronic condition, which is expected to drive future sales growth and market share expansion.
See More
Eli Lilly Completes Acquisition of Centessa Pharmaceuticals
- Acquisition Completed: Eli Lilly has finalized its acquisition of Centessa Pharmaceuticals for approximately $6.3 billion, aimed at expanding its neuroscience portfolio, particularly in sleep medicine.
- Drug Development Progress: Centessa's lead drug candidate, Cleminorexton, is undergoing Phase 2a clinical studies targeting narcolepsy and other sleep disorders, indicating significant market potential and therapeutic prospects.
- Financial Structure: Under the agreement, Lilly acquired Centessa for $38 per share in cash, along with a non-transferable contingent value right of up to $9 per share, potentially adding $1.5 billion in value upon achieving specific regulatory milestones.
- Market Performance: Lilly's stock has traded between $623.78 and $1,182.73 over the past year, currently priced at $1,111.53, reflecting a 0.51% increase from the previous trading day, indicating positive market sentiment regarding the acquisition.
See More
Cardinal Health Stock Trim Analysis
- Stock Trim: Cardinal Health (CAH) sold 50 shares, reducing its holdings to 375 shares and decreasing its portfolio weighting from 2.50% to 2.25%, reflecting a cautious approach to market fluctuations.
- Sector Performance: The healthcare sector has been the best-performing this week, with Cardinal Health, Johnson & Johnson, and Eli Lilly benefiting from this trend, indicating a strong rebound in the overall market.
- Price Recovery: Cardinal Health's stock has rallied 6% this week and 20% this month, reaching an all-time high on Thursday, marking a significant recovery since the Iran war, with investors optimistic about its future prospects.
- Target Price Increase: Following the trim, Cardinal Health's price target was raised from $225 to $245, aligning with market consensus, demonstrating confidence in the company's growth potential.
See More
Eli Lilly Maintains Lead in Diabetes Drug Market
- Clinical Trial Results: Eli Lilly showcased its drug retatrutide's clinical trial data at the American Diabetes Association meeting, demonstrating significant improvements for patients with knee osteoarthritis pain and sleep apnea, thereby solidifying its leading position in the weight-loss and diabetes drug market.
- Weight Loss Drug Progress: Lilly's Attain-1 and Attain-2 Phase 3 clinical trials revealed significant weight loss in women at all stages of menopause using its weight-loss pill Foundayo, indicating strong market potential and demand for this treatment.
- Intensifying Market Competition: While Eli Lilly is deemed the 'winner' of the ADA conference, Novo Nordisk also highlighted competitive advantages of its weight-loss drug CagriSema, particularly in type 2 diabetes treatment, reflecting the increasing intensity of market competition.
- Financial Performance Comparison: Eli Lilly reported a 56% revenue growth last quarter, driven by the successful launch of new drugs, while Novo Nordisk faced negative adjusted sales growth, suggesting increasing market pressure and a persistent valuation gap between the two companies.
See More
Eli Lilly Maintains Lead in Diabetes Drug Market
- Increased Market Competition: While Novo Nordisk showcased positive data for its weight-loss drug CagriSema at the ADA conference, RBC analyst Trung Huynh emphasized that Eli Lilly's lead in the diabetes drug market remains solid, indicating its competitive advantage.
- Significant Clinical Trial Results: Eli Lilly's presentation of retatrutide (triple G) at the ADA conference revealed meaningful improvements in patients suffering from knee osteoarthritis and sleep apnea, further solidifying its market position in weight-loss and diabetes management.
- Strong Financial Performance: Eli Lilly reported a remarkable 56% revenue growth last quarter, driven by the successful launch of new weight-loss and diabetes drugs, showcasing its sustained high growth potential, particularly with the successful market entry of Zepbound and Mounjaro.
- Notable Valuation Gap: Currently, Novo Nordisk's forward P/E ratio stands at 13.6 times, while Eli Lilly's is at 30 times, indicating that the valuation gap between the two may persist unless Novo Nordisk returns to positive growth or Eli Lilly's growth rate significantly slows down.
See More
IWB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: IWB's 52-week low is $334.22 and high is $415.11, with the latest trade at $402.98, indicating significant price movement that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade in 'units' rather than traditional shares, allowing for flexibility in responding to market demand, as these units can be created or destroyed.
- Liquidity Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights notable inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
Lilly Launches MedicareGLP-1Bridge Program for Obesity Treatments
- New Medicare Pathway: Lilly announced the MedicareGLP-1Bridge program effective July 1, 2026, allowing eligible Medicare Part D patients to access Foundayo and Zepbound for $50 per month, marking a significant increase in treatment options for obesity.
- Expanded Coverage: This program will provide broad GLP-1 drug coverage for Medicare Part D patients for the first time, potentially benefiting around 20 million eligible patients and promoting obesity treatment accessibility, particularly among adults aged 65 and older.
- Significant Clinical Outcomes: Clinical trials demonstrated that Foundayo and Zepbound resulted in meaningful weight loss in patients aged 65 and older, with Foundayo achieving an average weight loss of 13% in non-diabetic patients at the highest dose, while Zepbound showed over 56.7% of patients losing at least 20% of their body weight over 72 weeks, highlighting its effectiveness in older populations.
- Long-term Strategic Implications: This initiative not only enhances the accessibility of Lilly's obesity medications but also solidifies its leadership in chronic disease treatment, reflecting the company's commitment to recognizing obesity as a chronic condition, which is expected to drive future sales growth and market share expansion.
See More
Eli Lilly Completes Acquisition of Centessa Pharmaceuticals
- Acquisition Completed: Eli Lilly has finalized its acquisition of Centessa Pharmaceuticals for approximately $6.3 billion, aimed at expanding its neuroscience portfolio, particularly in sleep medicine.
- Drug Development Progress: Centessa's lead drug candidate, Cleminorexton, is undergoing Phase 2a clinical studies targeting narcolepsy and other sleep disorders, indicating significant market potential and therapeutic prospects.
- Financial Structure: Under the agreement, Lilly acquired Centessa for $38 per share in cash, along with a non-transferable contingent value right of up to $9 per share, potentially adding $1.5 billion in value upon achieving specific regulatory milestones.
- Market Performance: Lilly's stock has traded between $623.78 and $1,182.73 over the past year, currently priced at $1,111.53, reflecting a 0.51% increase from the previous trading day, indicating positive market sentiment regarding the acquisition.
See More
Cardinal Health Stock Trim Analysis
- Stock Trim: Cardinal Health (CAH) sold 50 shares, reducing its holdings to 375 shares and decreasing its portfolio weighting from 2.50% to 2.25%, reflecting a cautious approach to market fluctuations.
- Sector Performance: The healthcare sector has been the best-performing this week, with Cardinal Health, Johnson & Johnson, and Eli Lilly benefiting from this trend, indicating a strong rebound in the overall market.
- Price Recovery: Cardinal Health's stock has rallied 6% this week and 20% this month, reaching an all-time high on Thursday, marking a significant recovery since the Iran war, with investors optimistic about its future prospects.
- Target Price Increase: Following the trim, Cardinal Health's price target was raised from $225 to $245, aligning with market consensus, demonstrating confidence in the company's growth potential.
See More
Eli Lilly Maintains Lead in Diabetes Drug Market
- Clinical Trial Results: Eli Lilly showcased its drug retatrutide's clinical trial data at the American Diabetes Association meeting, demonstrating significant improvements for patients with knee osteoarthritis pain and sleep apnea, thereby solidifying its leading position in the weight-loss and diabetes drug market.
- Weight Loss Drug Progress: Lilly's Attain-1 and Attain-2 Phase 3 clinical trials revealed significant weight loss in women at all stages of menopause using its weight-loss pill Foundayo, indicating strong market potential and demand for this treatment.
- Intensifying Market Competition: While Eli Lilly is deemed the 'winner' of the ADA conference, Novo Nordisk also highlighted competitive advantages of its weight-loss drug CagriSema, particularly in type 2 diabetes treatment, reflecting the increasing intensity of market competition.
- Financial Performance Comparison: Eli Lilly reported a 56% revenue growth last quarter, driven by the successful launch of new drugs, while Novo Nordisk faced negative adjusted sales growth, suggesting increasing market pressure and a persistent valuation gap between the two companies.
See More
Eli Lilly Maintains Lead in Diabetes Drug Market
- Increased Market Competition: While Novo Nordisk showcased positive data for its weight-loss drug CagriSema at the ADA conference, RBC analyst Trung Huynh emphasized that Eli Lilly's lead in the diabetes drug market remains solid, indicating its competitive advantage.
- Significant Clinical Trial Results: Eli Lilly's presentation of retatrutide (triple G) at the ADA conference revealed meaningful improvements in patients suffering from knee osteoarthritis and sleep apnea, further solidifying its market position in weight-loss and diabetes management.
- Strong Financial Performance: Eli Lilly reported a remarkable 56% revenue growth last quarter, driven by the successful launch of new weight-loss and diabetes drugs, showcasing its sustained high growth potential, particularly with the successful market entry of Zepbound and Mounjaro.
- Notable Valuation Gap: Currently, Novo Nordisk's forward P/E ratio stands at 13.6 times, while Eli Lilly's is at 30 times, indicating that the valuation gap between the two may persist unless Novo Nordisk returns to positive growth or Eli Lilly's growth rate significantly slows down.
See More
IWB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: IWB's 52-week low is $334.22 and high is $415.11, with the latest trade at $402.98, indicating significant price movement that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade in 'units' rather than traditional shares, allowing for flexibility in responding to market demand, as these units can be created or destroyed.
- Liquidity Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights notable inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
